Ketorolac

Ketorolac (RS37619) is a non-steroidal anti-inflammatory drug (NSAID), acting as a nonselective COX inhibitor, with IC50s of 20 nM for COX-1 and 120 nM for COX-2. Ketorolac tromethamine is used as 0.5% ophthalmic solution for the research of allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Ketorolac tromethamine is also a DDX3 inhibitor that can be used for cancer research[1][4].

Product Specifications

CAS Number

[74103-06-3]

Product Name Alternative

RS37619

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; COX

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/ketorolac.html

Purity

99.93

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(C1C2=CC=C(C(C3=CC=CC=C3)=O)N2CC1)O

Molecular Formula

C15H13NO3

Molecular Weight

255.27

Precautions

H302, H315, H319, H335

References & Citations

[1]Waterbury LD, et al. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22 (6) :1133-40.|[2]Fracon RN, et al. Treatment with paracetamol, ketorolac or etoricoxib did not hinder alveolar bone healing: a histometric study in rats. J Appl Oral Sci. 2010 Dec;18 (6) :630-4.|[3]Hsieh YC, et al. Intrathecal ketorolac pretreatment reduced spinal cord ischemic injury in rats. Anesth Analg. 2005 Apr;100 (4) :1134-9.|[4]Samal SK, et al. Ketorolac salt is a newly discovered DDX3 inhibitor to treat oral cancer. Sci Rep. 2015 Apr 28;5:9982.